ExcitingAds! Avastin

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A).Divisional sales growth was 2%, reflecting the impact of the expected decline in sales of the COVID-19 medicine RonapreveDiagnostics Division base business2 grew by 8%,...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

EMA Approves Ocular Formulation of Bevacizumab EMA Approves Ocular Formulation of Bevacizumab

Medscape Pharmacist Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Europe has approved the use of monoclonal antibody bevacizumab for the treatment of neovascular age-related macular degeneration.Medscape Medical News (Source: Medscape Pharmacist Headlines)

Lonsurf/Bevacizumab for Advanced Metastatic Colorectal Cancer Lonsurf/Bevacizumab for Advanced Metastatic Colorectal Cancer

Medscape Today Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Dr David J. Kerr discusses the approval of the combination of Lonsurf (trifluridine-tipiracil) and bevacizumab in the third-line treatment of advanced metastatic colorectal cancer.Medscape Oncology (Source: Medscape Today Headlines)

Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

A new study showed improved progression-free survival when systemic therapy is added to TACE for HCC. Overall survival outcomes are pending.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong momentum in theDiagnostics Division ’s base businesscontinues with an increase of 7%Highlightsin the fourth quarter of 2023 and January 2024:US approval ofVabysmo (reti...

MedWorm Message:

Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

MONDAY, Jan. 29, 2024 -- For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) improves progression-free survival (PFS),... (Source: Drugs.com - Pharma News)

Atezolizumab Plus Standard Care Improves Survival in Advanced Cervical Cancer

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

FRIDAY, Jan. 5, 2024 -- For patients with metastatic, persistent, or recurrent cervical cancer, adding atezolizumab to a standard bevacizumab plus platinum regimen significantly improves progression-free and overall survival, according to a study... (Source: Drugs.com - Pharma News)

FDA Approves Avzivi (bevacizumab-tnjn), a Biosimilar to Avastin

Drugs.com - New Drug Approvals — Wed, 24 Apr 2024 11:51:33 +0100

GUANGZHOU, China, Dec. 7, 2023 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets, today announced that the United States Food and Drug... (Source: Drugs.com - New Drug Approvals)

Adding Atezolizumab Improves Survival in Advanced Cervical Cancer

MedPage Today Hematology/Oncology — Wed, 24 Apr 2024 11:51:33 +0100

(MedPage Today) -- First-line treatment with the anti-PD-L1 inhibitor atezolizumab (Tecentriq) combined with bevacizumab (Avastin) and platinum-based chemotherapy significantly improved survival in patients with metastatic or recurrent cervical... (Source: MedPage Today Hematology/Oncology)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, …

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

(Source: Reuters: Health)

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III data forAlecensa(early-stage lung cancer) andOcrevus(subcutaneous injection; multiple sclerosis)Positive phase II data forzilebesiran(hypertension ...

No Benefit to Extending Bevacizumab in Ovarian Cancer No Benefit to Extending Bevacizumab in Ovarian Cancer

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Maurie Markman, MD, discusses results from a pragmatic clinical trial regarding extended frontline treatment with bevacizumab in patients with ovarian cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)

FDA Approves Lonsurf (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC)

Drugs.com - New Drug Approvals — Wed, 24 Apr 2024 11:51:33 +0100

Approval clinical trial showing that treatment with Lonsurf plus bevacizumab resulted in statistically significant and clinically meaningful improvements in overall survival in patients with previously treated mCRC compared to Lonsurf as a single... (Source: Drugs.com - New Drug Approvals)

MedWorm Message:

FDA OKs Trifluridine/Tipiracil Plus Bevacizumab for mCRC FDA OKs Trifluridine/Tipiracil Plus Bevacizumab for mCRC

Medscape Gastroenterology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Medscape Medical News (Source: Medscape Gastroenterology Headlines)

FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer

FDA Center for Drug Evaluation and Research - What's New — Wed, 24 Apr 2024 11:51:33 +0100

(Source: FDA Center for Drug Evaluation and Research - What's New)

Sticker Shock: Ophthalmic Bevacizumab Biosimilar Could Drive Up Costs

MedPage Today Public Health — Wed, 24 Apr 2024 11:51:33 +0100

(MedPage Today) -- SEATTLE -- Availability of a bevacizumab (Avastin) biosimilar for ophthalmic use could have the unintended consequence of driving up the cost of treating retinal disease with angiogenesis inhibitors, according to an economic... (Source: MedPage Today Public Health)

What Are Treatments for Recurrent Respiratory Papillomatosis?

PediatricEducation.org — Wed, 24 Apr 2024 11:51:33 +0100

Discussion Human papilloma virus (HPV) is a member of the Papillomaviridae virus family with over a 150 different subtypes. HPV can cause cervical, genital and respiratory tract papillomas. HPV is often benign but can cause anogenital, cervical and head and neck cancers. Recurrent respiratory papillomatosis (RRP) is uncommon but can cause significant morbidity while awaiting the body’s immune system to respond. There is a juvenile and adult form, and the incidence varies between 2-4/100,000 in the pediatric population. The juvenile form frequently occurs between 3.6-6 years of age and in general the younger the patient, the more severe the disease. The RRP papillomas are histologically benign, exophytic lesions occurring after the virus invades the epithelial keratinocytes but becaus...

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower demand for COVID-19 products and a base effect from a patent settlement in 2022;IFRS net incomedown 9% due to lower core operating profit and higher interest expensesHig...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Can AI Help Determine If Liver Cancer Will Respond to Standard Treatment?

MedPage Today Gastroenterology — Wed, 24 Apr 2024 11:51:33 +0100

(MedPage Today) -- VIENNA -- Researchers trained an artificial intelligence (AI) model to determine if a patient with hepatocellular carcinoma (HCC) will respond to standard treatment with atezolizumab (Tecentriq) plus bevacizumab (Avastin)... (Source: MedPage Today Gastroenterology)

Trial Suggests Optimal Approach to Unresectable CRC Liver Mets

MedPage Today Gastroenterology — Wed, 24 Apr 2024 11:51:33 +0100

(MedPage Today) -- For patients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI plus bevacizumab (Avastin) was the "preferred" systemic induction regimen for those with a right-sided or RAS- or BRAF V600E-mutated primary... (Source: MedPage Today Gastroenterology)

ASCO: Adding Pembrolizumab to Chemo Improves Survival in Cervical Cancer

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

THURSDAY, June 1, 2023 -- For women with persistent, recurrent, or metastatic cervical cancer, adding pembrolizumab to chemotherapy, with or without bevacizumab, is associated with improved overall and progression-free survival, according to a study... (Source: Drugs.com - Pharma News)

Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC):Developing new treatment options for people with blood cancersExtended follow-up data for Columvi ® (glofitamab) of almost two years (20 months) from the pivotal phase II NP30179 study, further investigating the potential of fixed-duration Columvi to provide durable responses in people with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)Early data from the phase Ib NP40126 study of Columvi in combination with Polivy plus rituximab, cyclophosp...

MedWorm Message:

FTD-TPI Plus Bevacizumab Increases Survival in Refractory Advanced CRC

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

THURSDAY, May 4, 2023 -- Treatment with trifluridine-tipiracil (FTD-TPI) plus bevacizumab yields longer overall survival than FTD-TPI alone among patients with refractory metastatic colorectal cancer, according to a study published in the May 4... (Source: Drugs.com - Pharma News)

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of Polivy (first-line treatment for an aggressive form of blood cancer)EU approval ofHemlibra (moderate haemophilia A)Positive phase III data forVabysmo (retinal vein occlusion, a serious eye disease),Tecentriq plusAvastin (adjuvant therapy for certai...

Combo Therapy May Prevent Cancer's Return After Liver Surgery

Drugs.com - Daily MedNews — Wed, 24 Apr 2024 11:51:33 +0100

MONDAY, April 24, 2023 -- A two-drug combination therapy can enhance survival odds for people with early-stage liver cancer through targeted attacks on tumor cells, a new clinical trial shows. The combo -- atezolizumab (Tecentriq) and bevacizumab... (Source: Drugs.com - Daily MedNews)

Health Highlights: April 24, 2023

Drugs.com - Daily MedNews — Wed, 24 Apr 2024 11:51:33 +0100

Combo therapy may prevent cancer's return after liver surgery. Atezolizumab and bevacizumab are already used together to treat advanced liver cancer, now a new study finds it does the same for early-stage disease. Read more This is your brain on... (Source: Drugs.com - Daily MedNews)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

AACR: Adjuvant Atezolizumab + Bevacizumab Beneficial in Liver Cancer

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

TUESDAY, April 18, 2023 -- For patients with high-risk hepatocellular carcinoma (HCC), adjuvant therapy of atezolizumab with bevacizumab (atezo + bev) prolongs recurrence-free survival, according to a study presented at the annual meeting of the... (Source: Drugs.com - Pharma News)

Drug Combo Improves Recurrence-Free Survival After HCC Resection Drug Combo Improves Recurrence-Free Survival After HCC Resection

Medscape Medical News Headlines — Wed, 24 Apr 2024 11:51:33 +0100

The atezolizumab-bevacizumab combination is the first to show efficacy in the adjuvant setting after HCC resection for patients at high risk for recurrence, but the overall survival benefit is unclear.Medscape Medical News (Source: Medscape Medical News Headlines)

Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple international clinical guidelines.About the IMbrave050 studyIMbrave050 is a Phase III global, multicentre, open-label, randomised study evaluating the efficacy and safet...

Genentech ending commercial manufacturing, 265 jobs at 40-year-old South S.F. facility

bizjournals.com Health Care:Physician Practices headlines — Wed, 24 Apr 2024 11:51:33 +0100

The facility that produced the Genentech-defining cancer drugs Avastin and Herceptin as well as 10 others is stopping commercial manufacturing. (Source: bizjournals.com Health Care:Physician Practices headlines)

MedWorm Message:

USFDA issues CRL for Bevacizumab license application moved by Viatris: Biocon

The Economic Times Healthcare and Biotech News — Wed, 24 Apr 2024 11:51:33 +0100

"The USFDA has issued a CRL for the Biologics License Application (BLA) for Bevacizumab filed by our partner Viatris (Mylan)," a company spokesperson said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)

No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

In fact, the worst survival outcomes were seen with the most commonly used first-line regimen, FOLFOX chemotherapy plus the VEGF inhibitor bevacizumab.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymphoma),Tecentriq (advanced rare sarcoma) andActemra/RoActemra (COVID-19)US priority review ofglofitamab (aggressive form of blood cancer)Positive phase III data forVabysmo...

New Standard of Care for Refractory Metastatic Colorectal Cancer

MedPage Today Gastroenterology — Wed, 24 Apr 2024 11:51:33 +0100

(MedPage Today) -- SAN FRANCISCO -- Survival in treatment-refractory metastatic colorectal cancer (mCRC) improved by more than 3 months in patients who received bevacizumab (Avastin) in addition to chemotherapy, a randomized trial showed. Median... (Source: MedPage Today Gastroenterology)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

SUNLIGHT: New Standard of Care in Refractory Metastatic CRC SUNLIGHT: New Standard of Care in Refractory Metastatic CRC

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

The SUNLIGHT trial results show that adding bevacizumab to trifluridine/tipiracil (Lonsurf) improves median overall and progression free survival without increasing the risk for serious adverse events.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The st...

Atezolizumab Plus Bevacizumab: A New Standard for Some NSCLC? Atezolizumab Plus Bevacizumab: A New Standard for Some NSCLC?

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Encouraging findings with the combination suggest that it could offer a new standard treatment for patients with highly mutated non –small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

Shaken baby syndrome in an infant treated for retinopathy of prematurity with anti-VEGF injection - Devebacak A, Bekmez S, Eris E, Mayali H, Yurtseven I, Celik Y, Ba ğ Ö.

SafetyLit — Wed, 24 Apr 2024 11:51:33 +0100

We present the case of an infant who received bevacizumab treatment for retinopathy of prematurity (ROP) and developed retinal hemorrhages 12 weeks later. Although preretinal hemorrhages along the ROP's ridge were a concern for recurrence, we decided to in... (Source: SafetyLit)

MedWorm Message:

Bevacizumab, Aflibercept Compared for Neovascular AMD

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

MONDAY, Dec. 5, 2022 -- For patients with neovascular age-related macular degeneration (nvAMD), eyes treated with bevacizumab require more injections than those treated with aflibercept, and those receiving aflibercept are more likely to be weaned... (Source: Drugs.com - Pharma News)

FDA Approves Elahere (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer

Drugs.com - New Drug Approvals — Wed, 24 Apr 2024 11:51:33 +0100

Elahere is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin® Use VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the... (Source: Drugs.com - New Drug Approvals)

[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approvals forXofluza (influenza in children)Launch of a digital PCR diagnostic platform and of COVID-19, skin and breast cancer tests“Breakthrough Device Designation” granted...

FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin

Drugs.com - New Drug Approvals — Wed, 24 Apr 2024 11:51:33 +0100

Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option The approval is based on totality of... (Source: Drugs.com - New Drug Approvals)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follicular lymphoma) andTecentriq (early-stage lung cancer); EU marketing authorisation application submitted forglofitamab (blood cancer)US approval ofEvrysdi (babies under two months of age wit...

Diabetic Macular Edema Outcomes Compared for Aflibercept, Bevacizumab

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

FRIDAY, July 15, 2022 -- For treatment of diabetic macular edema involving the center of the macular, two-year outcomes are similar for those treated with aflibercept monotherapy and with bevacizumab first then a switch to aflibercept in cases of... (Source: Drugs.com - Pharma News)

Bevacizumab First Matches Aflibercept for Diabetic Macular Edema Bevacizumab First Matches Aflibercept for Diabetic Macular Edema

Medscape Diabetes Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Results from a randomized trial showed that step therapy for diabetic macular edema with lower-priced bevacizumab followed by pricier aflibercept, when needed, works as well as aflibercept monotherapy.Medscape Medical News (Source: Medscape Diabetes Headlines)

Panitumumab Beats Bevacizumab in Left-Sided mCRC Panitumumab Beats Bevacizumab in Left-Sided mCRC

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

The first trial comparing panitumumab or bevacizumab plus standard chemotherapy has shown that the former significantly improves survival in left-sided Ras wild type metastatic colorectal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

MedWorm Message:

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held 3-7 June, 2022. Roche and its partners will present clinical studies across medicines, comprehensive genomic tests, and real...

Which CRC Regimens Are More Likely to Harm Kidneys? Which CRC Regimens Are More Likely to Harm Kidneys?

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

After analyzing various treatments for metastatic colorectal cancer (CRC), researchers zeroed in on FOLFIRI + bevacizumab. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Alymsys (Bevacizumab-maly Injection) - updated on RxList

RxList - New and Updated Drug Monographs — Wed, 24 Apr 2024 11:51:33 +0100

(Source: RxList - New and Updated Drug Monographs)

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 25 April 2022Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cell lung cancer) and mosunetuzumab (follicular lymphoma)Positive long-term data for Evrysdi (spinal muscular atrophy) and for Vabysmo and Susvimo (sever...

Alymsys (Bevacizumab-maly Injection) - new on RxList

RxList - New and Updated Drug Monographs — Wed, 24 Apr 2024 11:51:33 +0100

(Source: RxList - New and Updated Drug Monographs)

FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin

Drugs.com - New Drug Approvals — Wed, 24 Apr 2024 11:51:33 +0100

BRIDGEWATER, N.J.--(BUSINESS WIRE) April 13, 2022 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the“Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s... (Source: Drugs.com - New Drug Approvals)

MedWorm Message:

Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Drugs.com - New Drug Applications — Wed, 24 Apr 2024 11:51:33 +0100

ISELIN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today... (Source: Drugs.com - New Drug Applications)

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals for diagnosticssince the last quarter: cobas 5800 (molecular laboratory system); Avenio Edge (sequencing sample preparation system); cobas pulse and cobas infin...

Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy

Asbestos and Mesothelioma News — Wed, 24 Apr 2024 11:51:33 +0100

This study recruited patients with unresectable pleural mesothelioma who had not received prior chemotherapy. The primary endpoint of median overall survival was significantly longer with the addition of bevacizumab to chemotherapy at 18.8 months versus 16.1 months with chemotherapy alone. However, adverse events such as hypertension and bleeding were more common in the bevacizumab group. More recently, studies such as the phase II RAMSES trial in 2020 have shown promising results for combining anti-VEGF medication with chemotherapy as a second-line treatment. The addition of the VEGF inhibitor ramucirumab significantly improved median overall survival to 13.8 months compared to 7.5 months for chemotherapy alone. Future clinical trials will undoubtedly build on the success of curr...

Bevacizumab and Gastrointestinal Perforations Bevacizumab and Gastrointestinal Perforations

Medscape Today Headlines — Wed, 24 Apr 2024 11:51:33 +0100

This study describes the demographic and clinical characteristics of this serious adverse event.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Bevacizumab-vikg Wet AMD Trial Raises Eyebrows Bevacizumab-vikg Wet AMD Trial Raises Eyebrows

Medscape Medical News Headlines — Wed, 24 Apr 2024 11:51:33 +0100

An'apples-to-oranges'comparison of bevacizumab-vikg to ranibizumab is troubling some experts who would like to see the drug approved.Medscape Medical News (Source: Medscape Medical News Headlines)

New Standard of Care in Cervical Cancer New Standard of Care in Cervical Cancer

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

The combination resulted in significant improvements in both progression-free and overall survival compared with chemotherapy (with or without bevacizumab) alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine

World Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF), a key mediator of angiogenesis in cancer, and is used in combination with other treatments(1,2). (Source: World Pharma News)

Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease

Asbestos and Mesothelioma News — Wed, 24 Apr 2024 11:51:33 +0100

We report the first real-world evidence regarding clinical outcomes for a cohort of patients with advanced MPeM receiving ICIs,” the MD Anderson study authors wrote. “Our results provide much-needed data supporting the role of ICIs in patients with this rare disease, who cannot participate in clinical trials and otherwise have no or limited treatment options.” The post Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)

New Drug Combination Shows Promise for Peritoneal Mesothelioma

Asbestos and Mesothelioma News — Wed, 24 Apr 2024 11:51:33 +0100

Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling a gaping void that exists today. The immunotherapy drug combination of Tecentriq and Avastin, known generically as atezolizumab and bevacizumab, respectively, showed unusual efficacy in a recent study of 20 patients with this rare cancer. Although some patients have previously found significant success and extended survival with the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combination, or HIPEC, those with unresectable disease have been left with no good options. Until now, possibly. The unique synergy between the study’s two drugs produced a safe and durable response with mesothelioma pa...

MedWorm Message:

Oncotarget: RAS reversion in colorectal cancer patients treated with bevacizumab

EurekAlert! - Cancer — Wed, 24 Apr 2024 11:51:33 +0100

(Impact Journals LLC) This Oncotarget finding might have potential therapeutic implications, as anti-EGFR could be reconsidered in primarily RAS mutant patients reverted to a wild-type status after bevacizumab exposure. (Source: EurekAlert! - Cancer)

Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient

EurekAlert! - Cancer — Wed, 24 Apr 2024 11:51:33 +0100

(University of Texas M. D. Anderson Cancer Center) A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen (Source: EurekAlert! - Cancer)

Edge Pharma Announces New Agreement with Cardinal Health ’s Acuity™ GPO

PRWeb: Medical Pharmaceuticals — Wed, 24 Apr 2024 11:51:33 +0100

Edge Pharma, a 503B Outsourcing Facility, has entered into an agreement with Cardinal Health’s Acuity™ GPO to provide its member ophthalmology practices with Edge’s unit-dose MVASI™ (Bevacizumab-awwb)...(PRWeb July 14, 2021)Read the full story at https://www.prweb.com/releases/edge_pharma_announces_new_agreement_with_cardinal_healths_acuity_gpo/prweb18065310.htm (Source: PRWeb: Medical Pharmaceuticals)

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

FDA Center for Drug Evaluation and Research - What's New — Wed, 24 Apr 2024 11:51:33 +0100

Hematology / Oncology Drug Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)

Drug Combination Disappoints in Advanced NSCLC Drug Combination Disappoints in Advanced NSCLC

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Second-line bevacizumab plus osimertinib showed some PFS benefit over osimertinib alone in a subset of smokers/former smokers but overall showed no survival benefits in the ETOP BOOSTER trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Intravitreal bevacizumab cost saving for macular oedema in the UK

PharmacoEconomics and Outcomes News — Wed, 24 Apr 2024 11:51:33 +0100

(Source: PharmacoEconomics and Outcomes News)

Genentech defends breast cancer drug a decade after Avastin drama

bizjournals.com Health Care:Pharmaceuticals headlines — Wed, 24 Apr 2024 11:51:33 +0100

"We all want to give patients hope — real hope, not false hope," said one opponent of allowing Genentech's Tecentriq to stay on the market. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

New Combo Shows Benefit Even in Patients With High-Risk HCC New Combo Shows Benefit Even in Patients With High-Risk HCC

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Updated data from the IMBRave150 trial show benefit for the combination of atezolizumab with bevacizumab even in patients with high-risk hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

Biocon Biologics, Viatris Inc. get CHMP nod for Abevmy, a biosimilar to Avastin

The Economic Times Healthcare and Biotech News — Wed, 24 Apr 2024 11:51:33 +0100

Abevmy is abiosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen, it said. (Source: The Economic Times Healthcare and Biotech News)

MedWorm Message:

Atezolizumab + bevacizumab unlikely cost-effective first-line option in HCC

PharmacoEconomics and Outcomes News — Wed, 24 Apr 2024 11:51:33 +0100

(Source: PharmacoEconomics and Outcomes News)

Anticancer drug may improve outcome for severe COVID-19 patients

World Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020. On average, blood oxygen levels, body temperature and inflammatory markers significantly improved in patients treated with a single dose of bevacizumab in addition to standard care. (Source: World Pharma News)

Drug 'breakthrough' gives longest-ever survival in nonresectable liver cancer patients

EurekAlert! - Cancer — Wed, 24 Apr 2024 11:51:33 +0100

(Spink Health) New follow-up data from a landmark study of liver cancer patients treated with a combination of an immunotherapy drug (atezolizumab) and a monoclonal antibody (bevacizumab) has shown the longest-ever survival time in a frontline phase 3 trial of systemic therapy in advanced hepatocellular carcinoma (HCC), demonstrating a 'major breakthrough' in the field. (Source: EurekAlert! - Cancer)

Researchers: Mesothelioma Trials Need More Inclusive Criteria

Asbestos and Mesothelioma News — Wed, 24 Apr 2024 11:51:33 +0100

Clinical trials for mesothelioma need more inclusive criteria to better reflect the patients being seen at major cancer treatment centers, according to a recent study conducted in Sydney, Australia. The study demonstrated a significant difference between those carefully selected for clinical trials and real-world patients with pleural mesothelioma. “A broader patient population more resembling real life would be able to access the novel treatment early,” Dr. Steven Kao, medical oncologist at Chris O’Brien Lifehouse hospital and one of the study authors, told The Mesothelioma Center at Asbestos.com. “And when the trial results are published, the efficacy results would be more applicable to the real-world population.” Clinical Lung Cancer published the study in 2020, accentuating ...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Jury's Still Out on Trifluridine/Tipiracil Plus Bev in mCRC Jury's Still Out on Trifluridine/Tipiracil Plus Bev in mCRC

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

First-line trifluridine/tipiracil plus bevacizumab offered a slight survival benefit over capecitabine plus bevacizumab in patients with unresectable metastatic colorectal cancer in the TASCO1 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)

USFDA informs Biocon Biologics, Mylan of deferred action on Avastin biosimilar license application

The Economic Times Healthcare and Biotech News — Wed, 24 Apr 2024 11:51:33 +0100

"To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the standard review process. However, due to restrictions on travel related to COVID-19, the agency is unable to conduct an inspection during the current review cycle. We await the dates for the inspection," Biocon said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of G lobal Product Development. “We’re delighted that people in Europe can now benefit from this combination and we look forward to working with individual countries wi...

MedWorm Message:

Biomarker Predicts Severe Hypertension With Bevacizumab Biomarker Predicts Severe Hypertension With Bevacizumab

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

A new biomarker may identify the 40% of patients with cancer who develop potentially life-threatening severe hypertension when treated with bevacizumab.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changing the treatment landscape for this aggressive disease”, said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “With almost half of the world’s hepatocellular carcinoma cases diagnosed i...

Bevacizumab Less Effective for Diabetic Macular Edema in Blacks

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

WEDNESDAY, Oct. 28, 2020 -- Black patients with diabetic macular edema are significantly less likely to show short-term visual improvement after one or three injections of bevacizumab, according to a study published online Oct. 9 in the American... (Source: Drugs.com - Pharma News)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Response to adjuvant bevacizumab among patients with resected melanoma may vary by age

EurekAlert! - Cancer — Wed, 24 Apr 2024 11:51:33 +0100

(American Association for Cancer Research) Younger patients with resected melanoma had some benefit from adjuvant treatment with the anti-VEGF therapeutic bevacizumab (Avastin) while older patients with resected melanoma did not. (Source: EurekAlert! - Cancer)

Researchers identify genetic variants linked to toxic side effects from bevacizumab

EurekAlert! - Cancer — Wed, 24 Apr 2024 11:51:33 +0100

(European Organisation for Research and Treatment of Cancer) In the largest study of its kind, researchers have found two common genetic variants that can be used to predict whether or not cancer patients might suffer severe adverse side-effects, such as high blood pressure, from the drug bevacizumab. The genome-wide association study is the largest such study in patients being treated with bevacizumab and it is to be presented at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. (Source: EurekAlert! - Cancer)

Tecentriq in combination with Avastin in 1L HCC approved in Japan

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Dear Investor, Please find attached a press release by Chugai:https://www.roche.com/200925_IR_eTecentriq_Avastin_HCC_approval.pdf Do not hesitate to contact us for any further questions. With best regards, (Source: Roche Investor Update)

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expected from the European Commission in the near future.“Today’s recommendation by the CHMP is a major step towards bringing Tecentriq in combination with Avastin to people in Eur...

Zirabev (Bevacizumab-bvzr Injection) - updated on RxList

RxList - New and Updated Drug Monographs — Wed, 24 Apr 2024 11:51:33 +0100

(Source: RxList - New and Updated Drug Monographs)

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoint of OS and data were immature at time of analysis. OS follow-up is planned to continue until final analysis. Safety for the Tecentriq combination appeared to be consistent wit...

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other types of thyroid cancer, as well as other solid tumours. In addition, pralsetinib has demonstrated tumour-agnostic potenti al. The companies also pla...

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers and is difficult to treat in its advanced stages,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “While we are disappointe...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Regeneron Funneled Kickbacks Through a Patient Charity, Federal Lawsuit Claims

NYT Health — Wed, 24 Apr 2024 11:51:33 +0100

The case is the latest inquiry into pharmaceutical companies ’ donations to patient assistance charities, which have been blamed for inflating the cost of drugs. (Source: NYT Health)

Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Triple-negative breast cancer remains an aggressive disease with high rates of recurrence,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Dev...

Roche Pharma India expands partnership with Cipla for key oncology medicines

The Economic Times Healthcare and Biotech News — Wed, 24 Apr 2024 11:51:33 +0100

Roche Pharma India has signed a "distribution agreement with Cipla to expand the scope of the partnership to include, marketing and distribution of its trademark oncology drugs - trastuzumab (Herclon), bevacizumab (Avastin) and rituximab (Ristova) in India," the company said in a statement. (Source: The Economic Times Healthcare and Biotech News)

Ramucirumab Shows Promise in Mesothelioma Clinical Trial

Asbestos and Mesothelioma News — Wed, 24 Apr 2024 11:51:33 +0100

Patients with pleural mesothelioma cancer experienced a significant survival advantage when ramucirumab, a novel immunotherapy drug, was added to chemotherapy in a treatment regimen. Ramucirumab, marketed by Eli Lilly and Company as Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. An ongoing phase II clinical trial in Italy recently reported almost double overall survival rates when ramucirumab was added to gemcitabine in second-line mesothelioma treatment. “These positive data may be the beginning to change the clinical practice in the choice of second-line therapy for pleural mesothelioma,” said oncologist Dr. Maria Pagano, General Hospital Arcispedale Santa Maria Nuova in Reggio Emilia, Italy. Ramu...

MedWorm Message:

Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

The combination use of niraparib plus bevacizumab significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer. (Source: CancerNetwork)

FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Investor Update)

Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

A study presented at the 2020 ASCO Scientific Program combining mirvetuximab soravtansine with bevacizumab to treat platinum-agnostic ovarian cancer demonstrated an encouraging overall response rate and tolerability profile regardless of platinum status. (Source: CancerNetwork)

FDA approves Roche immunotherapy cocktail in liver cancer

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

Swiss drugmaker Roche said on Friday that the U.S. Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with its drug Avastin for the most common kind of liver cancer. (Source: Reuters: Health)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

FDA Approves Genentech ’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma

Drugs.com - New Drug Approvals — Wed, 24 Apr 2024 11:51:33 +0100

South San Francisco, CA -- May 29, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) in combination... (Source: Drugs.com - New Drug Approvals)

FDA Approves Atezolizumab/Bevacizumab Combination for HCC

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. (Source: CancerNetwork)

Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

HSMN NewsFeed — Wed, 24 Apr 2024 11:51:33 +0100

The U.S. Food and Drug Administration reviewed the Company's request for Fast Track designation and concluded that investigation of onvansertib, in combination with FOLFIRI/bevacizumab, for second-line treatment of patients with KRAS-mutated metastatic col... Biopharmaceuticals, Oncology, FDA Cardiff Oncology, Onvansertib, Colorectal Cancer (Source: HSMN NewsFeed)

' Momentous' Data for First-Line Combo in Liver Cancer'Momentous' Data for First-Line Combo in Liver Cancer

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

The combination of atezolizumab and bevacizumab for the first-line treatment of unresectable hepatocellular carcinoma is set to become the new standard of care for this poor-prognosis cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

New treatment extends lives of people with most common type of liver cancer

UCLA Newsroom: Health Sciences — Wed, 24 Apr 2024 11:51:33 +0100

For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.Researchers found that a combination of atezolizumab, an immunotherapy drug that boosts the body ’s natural defenses, and bevacizumab, an anti-angiogenesis drug that inhibits the growth of tumors’ blood vessels, improved overall survival and reduced the risk of death by 42%. It also decreased the risk of the disease worsening by 41%, and the percentage of patients whose cancer shrank or disappeared more than doubled.Results from the clinical trial were published May 13 in the New England Journal of Medicine, and the drug combination is currently being reviewed for approval under the...

MedWorm Message:

Atezolizumab-Bevacizumab Beats Sorafenib in Liver Cancer

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

WEDNESDAY, May 13, 2020 -- Atezolizumab plus bevacizumab improves survival outcomes versus sorafenib in patients with unresectable hepatocellular carcinoma, according to a study published in the May 14 issue of the New England Journal of... (Source: Drugs.com - Pharma News)

FDA Approves Olaparib/Bevacizumab Maintenance FDA Approves Olaparib/Bevacizumab Maintenance

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

The FDA has announced a new approved indication for olaparib in adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

FDA Center for Drug Evaluation and Research - What's New — Wed, 24 Apr 2024 11:51:33 +0100

Hematology / Oncology Drug Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)

FDA Approves Expanded Olaparib Indication to Include Combination with Bevacizumab

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

The FDA expanded the indication of olaparib to include a combination regimen with bevacizumab for the first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)

Lynparza (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer

Drugs.com - New Drug Approvals — Wed, 24 Apr 2024 11:51:33 +0100

KENILWORTH, N.J.--(BUSINESS WIRE)--May 8, 2020 -- AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Lynparza in combination with... (Source: Drugs.com - New Drug Approvals)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Low Doses of Bevacizumab Tested for Retinopathy of Prematurity

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

FRIDAY, April 24, 2020 -- For treatment of retinopathy of prematurity (ROP), 0.004 mg may be the lowest effective dose of bevacizumab, according to a study published online April 23 in JAMA Ophthalmology. David K. Wallace, M.D., from the Jaeb Center... (Source: Drugs.com - Pharma News)

Very low-dose Avastin effective for preventing blindness in preterm infants

National Institutes of Health (NIH) News Releases — Wed, 24 Apr 2024 11:51:33 +0100

NIH-funded study finds very low doses effective for treating retinopathy of prematurity. (Source: National Institutes of Health (NIH) News Releases)

Bevacizumab plus paclitaxel not cost effective for HER2 − MBC

PharmacoEconomics and Outcomes News — Wed, 24 Apr 2024 11:51:33 +0100

(Source: PharmacoEconomics and Outcomes News)

Phase II Trial of Bevacizumab/Trebananib Combo Fails to Demonstrate Improvements

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Though the combination of bevacizumab and trebananib was found to be well tolerated, it did not significantly improve survival outcomes for patients with recurrent glioblastoma over bevacizumab alone. (Source: CancerNetwork)

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review

HSMN NewsFeed — Wed, 24 Apr 2024 11:51:33 +0100

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, March 9, 2020 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA... Biopharmaceuticals, Oncology, FDA Mylan, Biocon, biosimilar, Avastin, bevacizumab (Source: HSMN NewsFeed)

MedWorm Message:

FDA Accepts BLA for Proposed Biosimilar to Bevacizumab, MYL-1402O

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab. (Source: CancerNetwork)

US FDA accepts Biocon's cancer drug application for review

The Economic Times Healthcare and Biotech News — Wed, 24 Apr 2024 11:51:33 +0100

Biocon and Mylan ’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for patients in the US. (Source: The Economic Times Healthcare and Biotech News)

FDA grants Breakthrough Therapy Designation for Roche ’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 3 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet ® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD[1]. The study represented the first randomised controlled trial to exclusively enroll patients with progressive fibrosing uILD.“Today’s milestone for Esbriet builds on our continued commitment to improving the standard of care for people living with fibrotic lung diseases,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We look forward to disc...

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy available in China for the initial treatment of extensive-stage small cell lung cancer less than a year after the US FDA and EMA approvals, marking a swift and important step forward for p...

Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Basel, 7 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that additional data will be presented from a cohort of Chinese patients in the Phase III IMbrave150 study that evaluated Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Data from 194 Chinese patients who took part in the IMbrave150 study were consistent with the global results, that showed a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib. Among Chinese patients, Tecentriq in combination with Avastin reduced the risk of death (OS) by 56% (hazard ratio [HR]...

QoL Extended With Atezolizumab + Bevacizumab in Liver Cancer

The Doctors Lounge - Oncology — Wed, 24 Apr 2024 11:51:33 +0100

And, triplet and doublet drug regimens delay decline in quality of life in BRAF V600E metastatic CRC (Source: The Doctors Lounge - Oncology)

QoL Extended With Atezolizumab & #43; Bevacizumab in Liver Cancer

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

WEDNESDAY, Jan. 29, 2020 -- For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quality of life (QOL); and decline in... (Source: Drugs.com - Pharma News)

New Drug Combo Potentially Practice Changing in Advanced HCC New Drug Combo Potentially Practice Changing in Advanced HCC

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Atezolizumab plus bevacizumab was superior to sorafenib for maintaining quality of life in patients with unresectable hepatocellular carcinoma (HCC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early a s possible. In July 2018, the FDA granted Breakthrough Therapy Designation fo...

MedWorm Message:

Genentech Submits sBLA for Atezolizumab Plus Bevacizumab Combo to Treat Unresectable HCC

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

The company ’s application is based on results from the phase III IMbrave150 study of the regimen for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy. (Source: CancerNetwork)

Atezolizumab in Combination with Bevacizumab May Be Effective for Patients with HCC

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

High-quality patient reported outcomes were observed, suggesting benefits in key aspects of the patient experience with this combination treatment. (Source: CancerNetwork)

Activation of Apelin Signaling Decreases VEGF Inhibitor Efficacy in Ovarian Cancer Treatment

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

A recent study suggested the activation of apelin/APJ signaling decreased efficacy in VEGF treatment, while bevacizumab decreased disease-free survival rates with increased expression of apelin in patients of ovarian cancer. (Source: CancerNetwork)

Peer Influence May Lead to Subsequent Physician Adoption

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

In this study, researchers looked at the adoption and use of bevacizumab in order to identify opportunities to increase use of high-value therapies. (Source: CancerNetwork)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer

World Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted Priority Review in the US for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to 1st-line platinum-based chemotherapy with bevacizumab. (Source: World Pharma News)

FDA Grants Priority Review to Olaparib, Bevacizumab Combination for Ovarian Cancer

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

The priority review was based on results from the phase III PAOLA-1 trial comparing the addition of olaparib to bevacizumab vs the standard-of-care alone. (Source: CancerNetwork)

Addition of Maintenance Olaparib Slows Advanced Ovarian Cancer

Drugs.com - Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

WEDNESDAY, Dec. 18, 2019 -- Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian cancer, according to a study... (Source: Drugs.com - Pharma News)

Roche Says Tecentriq Cocktail Helps Liver Cancer Patients Live Longer Roche Says Tecentriq Cocktail Helps Liver Cancer Patients Live Longer

Medscape Allergy Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Swiss drugmaker Roche on Friday said its immunotherapy Tecentriq combined with its Avastin medicine helped people with the most common form of liver cancer to live longer than with an older drug from Germany's Bayer.Reuters Health Information (Source: Medscape Allergy Headlines)

Roche says Tecentriq cocktail helps liver cancer patients live longer

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

MedWorm Message:

Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche will today present positive results from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab). The data show statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)

Combination of immunotherapy and VEGF inhibitor improves survival in HCC

EurekAlert! - Cancer — Wed, 24 Apr 2024 11:51:33 +0100

(European Society for Medical Oncology) Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) compared to standard of care, showed results from a phase 3 study to be reported at the ESMO Asia 2019 Congress. (Source: EurekAlert! - Cancer)

FDA Accepts Biologics License Application for Bevacizumab Biosimilar

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Samsung Bioepis announced that the FDA accepted a biologics license application for SB8, a biosimilar candidate for bevacizumab. (Source: CancerNetwork)

Questions Over Value of Bevacizumab in Many Cancers Questions Over Value of Bevacizumab in Many Cancers

Medscape Medical News Headlines — Wed, 24 Apr 2024 11:51:33 +0100

The value of bevacizumab in the treatment of many cancers has been questioned, given that it has been approved mostly on the basis of progression-free, and not overall, survival benefits.Medscape Medical News (Source: Medscape Medical News Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Roche pushes late-comer Tecentriq as new liver cancer option

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

Roche's Tecentriq mixed with Avastin helped liver cancer patients live longer, a boost to the Swiss drugmaker's strategy of expanding its late-to-the-game immunotherapy into niche areas not yet dominated by rivals. (Source: Reuters: Health)

Roche ’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced that the Phase III IMbrave150 study, evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements i n overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib. (Source: Roche Investor Update)

Nivolumab and Bevacizumab Combo Shows Activity in Ovarian Cancer

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Combination therapy with nivolumab and bevacizumab appeared to have clinical activity in ovarian cancer patients with platinum-sensitive or platinum-resistant disease. (Source: CancerNetwork)

Olaparib Plus Bevacizumab Prolongs Survival in Advanced Ovarian Cancer

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Adding PARP inhibitors to maintenance therapy was shown to prolong progression-free survival in patients with advanced ovarian cancer. (Source: CancerNetwork)

MedWorm Message:

First-line Immunotherapy Still Elusive in Advanced Liver Cancer First-line Immunotherapy Still Elusive in Advanced Liver Cancer

Medscape Medical News Headlines — Wed, 24 Apr 2024 11:51:33 +0100

First-line immunotherapy remains elusive for patients with hepatocellular carcinoma (HCC), but early results look good for a combination with bevacizumab.Medscape Medical News (Source: Medscape Medical News Headlines)

Roche ’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche will today present results from a Phase Ib study evaluating the efficacy and safety of Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer, who have not received prior systemic therapy. (Source: Roche Media News)

Medicines regulator accepts ‘off label’ use of Avastin for wet AMD

OnMedica Latest News — Wed, 24 Apr 2024 11:51:33 +0100

Move will enable thousands of patients to be treated at fraction of the cost, say commissioners Related items fromOnMedica New cancer drug ‘refused’ by NICE Experts call on regulators to revisit nalmefene decision 75% of reappraised CDF drugs approved for NHS Controversial new drug approval system unveiled MPs slam government for its poor management of Cancer Drugs Fund (Source: OnMedica Latest News)

UCLA oncologist Dennis Slamon wins 2019 Lasker Award for clinical medical research

UCLA Newsroom: Health Sciences — Wed, 24 Apr 2024 11:51:33 +0100

Physician-scientist Dr. Dennis Slamon, professor and chief of hematology/oncology at the David Geffen School of Medicine at UCLA, has been awarded the 2019 Lasker-DeBakey Clinical Medical Research Award for the groundbreaking development of breast cancer drug Herceptin (trastuzumab), a lifesaving therapy for women with HER2-positive breast cancer. He shares the award with H. Michael Shepard, an American cancer researcher honored for work he completed at biotechnology company Genentech; and Axel Ullrich, a German cancer researcher from the Max Planck Institute of Biochemistry.The Albert and Mary Lasker Foundation honored Slamon and colleagues for demonstrating that monoclonal antibodies — proteins that bind to specific invader organisms or abnormal (e.g., cancerous) cells — were a viabl...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Genentech nears trade secrets suit settlement with Taiwanese company but still targeting former employees

bizjournals.com Health Care:Pharmaceuticals headlines — Wed, 24 Apr 2024 11:51:33 +0100

Biotech powerhouse Genentech Inc. is close to settling a with a Taiwanese company that allegedly stole trade secrets and planned to launch a look-alike version of one of Genentech's most popular drugs. The settlement between the South San Francisco-based U.S. unit of drug giant Roche and JHL Biotech Inc. requires the Taiwanese company to stop development of biosimilar versions of Genentech's cancer drugs Rituxan, Herceptin and Avastin — all multibillion-dollar biologics — and the cystic fibr osis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

Pacifico National, Inc. dba AmEx Pharmacy Issues Voluntary Nationwide Recall for all Lots of Bevacizumab

FDA Center for Drug Evaluation and Research - What's New — Wed, 24 Apr 2024 11:51:33 +0100

AmEx Pharmacy today announces a voluntary recall of all Lots of Bevacizumab 1.25mg/0.05mL 31G Injectable and all Lots of Bevacizumab 2.5mg/0.1ml Normject TB Injectable that are within expiry to the healthcare provider level. These lots are being recalled out of an abundance of caution following an F (Source: FDA Center for Drug Evaluation and Research - What's New)

Pacifico National, Inc. dba AmEx Pharmacy Issues Voluntary Nationwide...

PRWeb: Medical Pharmaceuticals — Wed, 24 Apr 2024 11:51:33 +0100

AmEx Pharmacy today announces a voluntary recall of all Lots of Bevacizumab 1.25mg/0.05mL 31G Injectable and all Lots of Bevacizumab 2.5mg/0.1ml Normject TB Injectable that are within expiry to the...(PRWeb August 30, 2019)Read the full story at https://www.prweb.com/releases/pacifico_national_inc_dba_amex_pharmacy_issues_voluntary_nationwide_recall_for_all_lots_of_bevacizumab/prweb16539042.htm (Source: PRWeb: Medical Pharmaceuticals)

Dr Reddy's launches Roche's Avastin biosimilar in India

The Economic Times Healthcare and Biotech News — Wed, 24 Apr 2024 11:51:33 +0100

The launch of Versavo is another step in that journey and helps in strengthening the company's oncology portfolio. (Source: The Economic Times Healthcare and Biotech News)

MedWorm Message:

Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer

World Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer. The trial, in the 1st-line maintenance setting, compared Lynparza (olaparib) added to standard-of-care (SoC) bevacizumab vs. bevacizumab alone in women with or without BRCA gene mutations. (Source: World Pharma News)

What Is the Optimal Maintenance Therapy in Advanced NSCLC?

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

A phase III trial found bevacizumab and pemetrexed were effective as a maintenance therapy, but researchers do not recommend it to treat non–small-cell lung cancer. (Source: CancerNetwork)

Bevacizumab Benefit in Large-Volume Ovarian Cancer Bevacizumab Benefit in Large-Volume Ovarian Cancer

Medscape Hematology-Oncology Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Although there was no benefit in overall survival in the primary treatment of ovarian cancer with maintenance bevacizumab, some hope remains for patients with large-volume disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

Amgen and Allergan's MVASI ™ (bevacizumab-awwb) and KANJINTI™ (trastuzumab-anns) now available in the United States

World Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.). (Source: World Pharma News)

Amgen, Allergan launch first anti-cancer biosims in U.S.

PharmaManufacturing.com — Wed, 24 Apr 2024 11:51:33 +0100

Amgen and Allergan have announced the launch of Mvasi, a bevacizumab biosimilar referencing Avastin, and Kanjinti, a trastuzumab biosimilar referencing Herceptin, in the United States. (Source: PharmaManufacturing.com)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Avastin Improves Quality of Life for Mesothelioma Patients

Asbestos and Mesothelioma News — Wed, 24 Apr 2024 11:51:33 +0100

A research team from France has documented the health-related quality-of-life benefits of adding Avastin (bevacizumab) to chemotherapy for pleural mesothelioma patients, endorsing its addition to standard-of-care treatment. The recent quality-of-life analysis was a secondary endpoint of an earlier, multicenter clinical trial in France that showed an almost three-month median survival improvement when adding Avastin. The latest study demonstrated that adding Avastin to cisplatin and Alimta (pemetrexed) did not negatively impact quality of life — a problem with several other cancers because of the increased toxicity. “Contrasting results of health-related quality of life have been reported with the combination in different types of tumors,” Dr. Virginie Westeel, co-author and head of t...

Zirabev (Bevacizumab-bvzr Injection) - new on RxList

RxList - New and Updated Drug Monographs — Wed, 24 Apr 2024 11:51:33 +0100

(Source: RxList - New and Updated Drug Monographs)

Mvasi (Bevacizumab-awwb Solution for Intravenous Infusion) - updated on RxList

RxList - New and Updated Drug Monographs — Wed, 24 Apr 2024 11:51:33 +0100

(Source: RxList - New and Updated Drug Monographs)

Pfizer's Avastin biosimilar wins FDA approval

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

Pfizer Inc said on Friday that the U.S. Food and Drug Administration had approved its biosimilar to Roche Holding AG's blockbuster cancer treatment Avastin. (Source: Reuters: Health)

FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin

Drugs.com - New Drug Approvals — Wed, 24 Apr 2024 11:51:33 +0100

Friday, June 28, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved Zirabev (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab),1 for the treatment of five types... (Source: Drugs.com - New Drug Approvals)

MedWorm Message:

Discouraging OS Results With Bevacizumab in Ovarian Cancer

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Long-term follow-up of a phase III trial showed overall survival results for bevacizumab plus chemotherapy in women with ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)

RXQ Compounding Recalls All'Sterile' Product RXQ Compounding Recalls All'Sterile' Product

Medscape Medical News Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Sterility concerns prompt RXQ Compounding to recall all unexpired sterile products, including injectable bevacizumab, epinephrine, ketamine, fentanyl, and midazolam, among others.News Alerts (Source: Medscape Medical News Headlines)

Adding Bevacizumab Improves Overall Survival in NSCLC

The Doctors Lounge - Oncology — Wed, 24 Apr 2024 11:51:33 +0100

Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non - small cell lung cancer (Source: The Doctors Lounge - Oncology)

Identifying colorectal cancer subtypes could lead to improved treatment decisions

EurekAlert! - Medicine and Health — Wed, 24 Apr 2024 11:51:33 +0100

(University of Southern California - Health Sciences) Identifying a metastatic colorectal cancer patient's Consensus Molecular Subtype could help oncologists determine the most effective course of treatment. For example, Survival for CMS1 patients on bevacizumab was twice that of those on cetuximab, whereas survival for CMS2 patients on cetuximab was six months longer than for bevacizumab. (Source: EurekAlert! - Medicine and Health)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Dr. Ramalingam on Pemetrexed and Bevacizumab as Maintenance Therapy for Advanced NSCLC

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Cancer Network spoke with Suresh S. Ramalingam, MD, of Emory University, about pemetrexed, bevacizumab, or both for advanced non-squamous NSCLC. (Source: CancerNetwork)

Effect of Anti-Angiogenesis/Immunotherapy Combo in Poor-Risk RCC

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Findings from a planned subanalysis of IMmotion151 looked at combination atezolizumab and bevacizumab in patients with RCC and sarcomatoid histology. (Source: CancerNetwork)

Patient Outcomes for Atezolizumab vs Sunitinib in Renal Cell Carcinoma

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

The phase II IMmotion150 study evaluated disease- and treatment-related symptoms in RCC patients receiving atezolizumab alone or in combination with bevacizumab vs sunitinib. (Source: CancerNetwork)

Addition of Maintenance Therapy Did Not Meet Primary Endpoint in Lung Cancer Trial

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

The addition of pemetrexed to bevacizumab maintenance therapy after induction therapy for chemo-naive patients with advanced lung cancer did not meet the primary endpoint in a phase III trial. (Source: CancerNetwork)

Can Adding Bevacizumab Improve Outcomes in Mucosal Melanoma?

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Researchers tested a combination regimen of bevacizumab with carboplatin and paclitaxel as a first-line treatment for patients with advanced mucosal melanoma. (Source: CancerNetwork)

MedWorm Message:

Combo Therapy More Than Doubled PFS in Platinum-Sensitive Recurrent Ovarian Cancer

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

The phase II AVANOVA trial examined PFS in advanced ovarian cancer patients who received a PARP inhibitor plus bevacizumab. (Source: CancerNetwork)

AmEx Pharmacy Issues Voluntary Nationwide Recall for one Lot of Bevacizumab 1.25mg/0.05mL 31 G Syringe Due to Reported Defective Delivery System

FDA Center for Drug Evaluation and Research - What's New — Wed, 24 Apr 2024 11:51:33 +0100

AmEx Pharmacy is voluntarily recalling one Lot of Bevacizumab 1.25mg/0.05mL 31G Injectable to the consumer/user level. The Monoject Syringe of this product may become difficult to express, and when additional force is applied, while the needle is in the eye, may cause injury to the patient. (Source: FDA Center for Drug Evaluation and Research - What's New)

Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced positive additional results of a prespecified exploratory analysis from the Phase III IMpower150 study, which demonstrated that the combination of Tecentriq ® (atezolizumab), Avastin® (bevacizumab), carboplatin and paclitaxel (chemotherapy) gave patients with chemotherapy-naïve, metastatic non-squamous non-small cell lung cancer (NSCLC), with baseline liver metastases an overall survival (OS) advantage compared with the combination of Avastin and che motherapy (median OS=13.3 vs 9.4 months; hazard ratio [HR]=0.52; 95% CI: 0.33–0.82) in the intention-to-treat (ITT) population. (Source: Roche Media News)

VISNU-1: FOLFOXIRI vs FOLFOX as First-Line Treatment in Metastatic Colorectal Cancer

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

A longer progression-free survival with FOLFOXIRI plus bevacizumab was noted in patients with metastatic colorectal cancer with poor prognosis. (Source: CancerNetwork)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Atezolizumab Plus Bevacizumab Might Help Some With Kidney Cancer Atezolizumab Plus Bevacizumab Might Help Some With Kidney Cancer

Medscape Allergy Headlines — Wed, 24 Apr 2024 11:51:33 +0100

The anti-VEGF monoclonal antibody bevacizumab combined with the anti-PD-L1 antibody atezolizumab might beat sunitinib in some patients with previously untreated advanced renal-cell carcinoma (RCC), but uncertainty remains, according to a phase 3 trial.Reuters Health Information (Source: Medscape Allergy Headlines)

SGO 2019: Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Results of a phase II trial evaluating pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide were presented at SGO 2019. (Source: CancerNetwork)

Roche gets European approval for Tecentriq combo vs. lung cancer

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

Roche has received European Commission approval for its Tecentriq drug in combination with Avastin and chemotherapy as an initial treatment for people with a specific type of lung cancer, the Swiss pharma company said on Friday. (Source: Reuters: Health)

European Commission approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)

How Does Bev + Chemo Perform in'Real World' Ovarian Cancer? How Does Bev + Chemo Perform in'Real World' Ovarian Cancer?

Medscape Today Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Patients in the nonresearch setting receiving bevacizumab with chemotherapy for ovarian cancer have impressive progression-free survival rates, says Maurie Markman.Medscape Oncology (Source: Medscape Today Headlines)

UCLA ’s Dennis Slamon awarded Sjöberg Prize for pioneering cancer research

UCLA Newsroom: Health Sciences — Wed, 24 Apr 2024 11:51:33 +0100

Dr. Dennis Slamon, director of the Revlon/UCLA Women ’s Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation. Honored for his groundbreaking research that led to the development of successful targeted cancer therapies, Slamon shares the award with D r. Brian Druker of Oregon Health& Science University.The Sj öberg Prize has been awarded annually since 2016 to recognize outstanding cancer research. The honor carries a prize of $1 million — $100,000 as award money and $900,000 to fund future research — which Slamon and Druker will split equally. Among the previous honorees is Dr. James Allison of the University of Texas MD Anderson Cancer Center, who went on to win the Nobel Prize...

CHMP recommends EU approval of Roche ’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) . (Source: Roche Investor Update)

Apatinib Case Study Uncovers Potential Mesothelioma Treatment

Asbestos and Mesothelioma News — Wed, 24 Apr 2024 11:51:33 +0100

Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma. Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment. After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival. “I was surprised at the result,” Meng told The Mesothelioma Center at Asbestos.com. “After taking the drug, the quality of life was good, and she lived longer.” Meng believes it was the first time Apatinib had been used and reported for pleural mesothelioma. The medical journal Medicine published the...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Pfizer's cut-price version of Avastin wins EU panel greenlight

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin. (Source: Reuters: Health)

Pfizer receives positive CHMP opinion for oncology biosimilar, ZIRABEV ™ (bevacizumab)

World Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for ZIRABEV™ (bevacizumab), a potential biosimilar to Avastin (bevacizumab). (Source: World Pharma News)

Roche wins key lung cancer combo approval

PharmaManufacturing.com — Wed, 24 Apr 2024 11:51:33 +0100

Roche Holding ’s Tecentriq immunotherapy, in combination with Avastin and chemotherapy, won U.S. FDA approval as a first-line treatment for a type of lung cancer. (Source: PharmaManufacturing.com)

FDA approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Media News)

FDA Approves Genentech ’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Drugs.com - New Drug Approvals — Wed, 24 Apr 2024 11:51:33 +0100

South San Francisco, CA -- December 6, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with... (Source: Drugs.com - New Drug Approvals)

Capecitabine + bevacizumab in CRC: small benefit, high cost in US

PharmacoEconomics and Outcomes News — Wed, 24 Apr 2024 11:51:33 +0100

(Source: PharmacoEconomics and Outcomes News)

Avastin: updated statement on its use for the treatment of wet AMD

Royal Pharmaceutical Society News — Wed, 24 Apr 2024 11:51:33 +0100

The recent judicial review ruling finds the use of Avastin (bevacizumab) in the NHS for the treatment of wet AMD to be lawful. Whilst we recognise the financial savings that could be made by switching (Source: Royal Pharmaceutical Society News)

Companies plan to appeal ruling on bevacizumab for wet AMD

PharmacoEconomics and Outcomes News — Wed, 24 Apr 2024 11:51:33 +0100

(Source: PharmacoEconomics and Outcomes News)

MedWorm Message:

Updated data showed that Roche's Tecentriq in combination with Avastin shrank tumours in people with unresectable or advanced hepatocellular carcinoma (HCC)

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Roche will today present updated data from a Phase Ib study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable or advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Investor Update)

UK Study Matches Mesothelioma Treatments to Genetic Profile

Asbestos and Mesothelioma News — Wed, 24 Apr 2024 11:51:33 +0100

University of Leicester researchers soon will open the first molecularly stratified clinical trial for malignant mesothelioma with the hope of moving the future of treatment toward more personalization. The phase II trial in the United Kingdom is designed to match therapy with a patient’s specific genetic profile. “We’re trying to bring the right drug to the right patient at the right time,” Professor Dean Fennell, chair of thoracic medical oncology at Leicester and chief trial investigator, told Asbestos.com. “We need to find different treatments that work for different people. This is a step in that direction.” The British Lung Foundation funded the clinical trial, which is expected to start early in 2019 and conclude by 2022. “The problem with mesothelioma has been the on...

Chromosomal instability may predict patients that will benefit from colorectal cancer drug

EurekAlert! - Biology — Wed, 24 Apr 2024 11:51:33 +0100

(RCSI) Researchers at RCSI, along with international collaborators within the ANGIOPREDICT research consortium, have discovered that chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients will receive most benefit from a key drug used to treat colorectal cancer (Avastin). (Source: EurekAlert! - Biology)

Legal battle in England to enable use of Avastin for wet AMD

PharmacoEconomics and Outcomes News — Wed, 24 Apr 2024 11:51:33 +0100

(Source: PharmacoEconomics and Outcomes News)

NHS wins landmark High Court battle with two major drug firms

the Mail online | Health — Wed, 24 Apr 2024 11:51:33 +0100

A judge rejected an action brought by Bayer and Novartis against 12 NHS clinical commissioning groups in north England relating to Avastin, an age-related macular degeneration drug. (Source: the Mail online | Health)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Avastin/Lucentis/Eylea ruling good news for patients, says RPS

Royal Pharmaceutical Society News — Wed, 24 Apr 2024 11:51:33 +0100

Responding to news that the NHS will allow Avastin to be prescribed for age related wet macular degeneration, RPS President Ash Soni said:“This is a landmark ruling and good news for patients (Source: Royal Pharmaceutical Society News)

Surgery for Mesothelioma No Longer Recommended in UK

Asbestos and Mesothelioma News — Wed, 24 Apr 2024 11:51:33 +0100

Aggressive surgery for the treatment of malignant pleural mesothelioma (MPM) — unless part of a clinical trial — is no longer being recommended in the United Kingdom. The British Thoracic Society recently published its Mesothelioma Management Guidelines for 2018 and removed surgery from its recommendations. The belief was that potential harm was not worth the risk. The backtrack on surgery included the extrapleural pneumonectomy (EPP), the extended pleurectomy and decortication (P/D) and the partial pleurectomy (PP) — all of which are being done at cancer centers in the United States. “Surgery is a controversial area. There is a difference of opinion, from our practice in the U.K. and much of Europe, than the practice in the [United] States,” Dr. Anna Bibby, Bristol Medical Schoo...

Roche Provides Update on Supplemental Biologics License Application (sBLA) for TECENTRIQ in First-line Metastatic Non-Squamous NSCLC

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

On September 05 2018, Roche was notified by the U.S. Food and Drug Administration (FDA) that the review period for the supplemental Biologics License Application (sBLA) for TECENTRIQ ® (atezolizumab) in combination with Avastin® (bevacizumab), carboplatin and paclitaxel for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) has been extended by three months. (Source: Roche Investor Update)

Should Colorectal Tumor Sidedness Affect Chemotherapy Choice? Should Colorectal Tumor Sidedness Affect Chemotherapy Choice?

Medscape Today Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Dr David Kerr discusses a recent case in the context of data supporting triplet chemotherapy plus bevacizumab in colorectal cancer.Medscape Oncology (Source: Medscape Today Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Adjuvant Bevacizumab Fails to Help in High-Risk Breast Cancer

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

The addition of bevacizumab to adjuvant chemotherapy regimens does not improve survival in women with high-risk breast cancer. (Source: CancerNetwork)

Report: IBM Watson delivered ‘unsafe and inaccurate’ cancer recommendations

Mass Device — Wed, 24 Apr 2024 11:51:33 +0100

Internal documents from IBM Watson Health (NYSE:IBM) indicate that the company’s Watson for Oncology product often returns “multiple examples of unsafe and incorrect treatment recommendations,” according to a new report from STAT News. The documents come from slides presented last year by IBM Watson Health’s deputy chief health officer, according to the report, and include feedback from customers that indicated the product is “often inaccurate” and that its recommendations bring to light “serious questions about the process for building content and the underlying technology.” The issues were blamed on training the Watson product received by IBM engineers and physicians at the Memorial Sloan Kettering Cancer Center, which included “synthetic,&#...

Can Bevacizumab Be Recommended in High-Risk Melanoma?

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Treatment of high-risk melanoma with adjuvant bevacizumab following resection improves disease-free survival over standard observation, but not overall survival. (Source: CancerNetwork)

FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)

World Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: World Pharma News)

FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Media News)

MedWorm Message:

Bevacizumab Rechallenge Benefit in Recurrent Ovarian Cancer?

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer. (Source: CancerNetwork)

FDA approves Roche ’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced that the US Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection. (Source: Roche Media News)

FDA Approves Genentech ’s Avastin (bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery

Drugs.com - New Drug Approvals — Wed, 24 Apr 2024 11:51:33 +0100

South San Francisco, CA -- June 13, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab) in combination with chemotherapy... (Source: Drugs.com - New Drug Approvals)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Nintedanib ‘ Superior ’ to Bevacizumab for Mesothelioma Treatment

Asbestos and Mesothelioma News — Wed, 24 Apr 2024 11:51:33 +0100

Researchers in Austria, Germany and Hungary have added to the growing belief that the anti-cancer drug nintedanib may soon become a significant part of standard-of-care treatment for malignant pleural mesothelioma. In their study published recently in Clinical Cancer Research, nintedanib demonstrated an ability to inhibit the growth and the migration of mesothelioma tumor cells effectively in animal models. “This is a step in the right direction, another part of the evolutionary process of treatment advancements with this difficult disease,” Dr. Balazs Hegedus, department of thoracic surgery, University of Duisburg-Essen, told Asbestos.com. “This is an important finding.” Nintedanib, also known by brand names Ofev and Vargetef, works by targeting a specific molecule expressed by m...

Second-Line Irinotecan/Cetuximab/Ramucirumab Combo Ups PFS in Advanced CRC

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

John SchieszerJun 6, 2018A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab –based therapy. (Source: CancerNetwork)

PFS Rises in Ovarian Ca with Repeat Bevacizumab

MedPage Today Hematology/Oncology — Wed, 24 Apr 2024 11:51:33 +0100

(MedPage Today) -- Magnitude of benefit similar to first-line therapy (Source: MedPage Today Hematology/Oncology)

Atezolizumab Increases Progression-free Survival in Lung Cancer Patients – Study Atezolizumab Increases Progression-free Survival in Lung Cancer Patients – Study

Medscape Medical News Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Adding atezolizumab to a combination of bevacizumab, carboplatin and paclitaxel gives patients with metastatic nonsquamous non-small-cell lung cancer better odds of progression-free and overall survival, a new study of 692 patients with wild-type disease has concluded.Reuters Health Information (Source: Medscape Medical News Headlines)

Patients Report Better RCC Outcomes for Atezolizumab + Bevacizumab

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Bryant FurlowJun 4, 2018Patients treated for RCC with atezolizumab plus bevacizumab reported fewer impacts to daily function and quality of life than those on sunitinib. (Source: CancerNetwork)

MedWorm Message:

Bevacizumab most cost-effective treatment for AMD

PharmacoEconomics and Outcomes News — Wed, 24 Apr 2024 11:51:33 +0100

(Source: PharmacoEconomics and Outcomes News)

Cancer nurse, 43, is overcoming the disease after strangers donated for a drug not on the NHS

the Mail online | Health — Wed, 24 Apr 2024 11:51:33 +0100

Last March, mother-of-two Laura Harris, 43, from Devon, who has advanced bowel cancer, was given just three months to live unless she could raise £21,000 to be treated by the drug Bevacizumab. (Source: the Mail online | Health)

mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States

HSMN NewsFeed — Wed, 24 Apr 2024 11:51:33 +0100

The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment MADRID, May 23, 2018 -- (Healthcare Sales & Marketing Network) -- mAbxience, a company specialize... Biopharmaceuticals, Generics, Licensing mAbxience, Insud Pharma Group, Amneal Pharmaceuticals, bevacizumab, biosimilar (Source: HSMN NewsFeed)

Phase III IMpower150 study showed Roche ’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced positive results from the Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)

Roche immunotherapy combination increases lung cancer survival - study

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

(Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday. (Source: Reuters: Health)

FDA grants priority review to Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer

World Pharma News — Wed, 24 Apr 2024 11:51:33 +0100

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: World Pharma News)

Roche's Tecentriq combo wins fast FDA review in race to catch rivals

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

ZURICH (Reuters) - Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday. (Source: Reuters: Health)

Roche's Tecentriq combination to get speedy FDA review

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

ZURICH (Reuters) - Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get a speeded-up review by U.S. regulators for use in initial treatment of people with a common form of lung cancer, the Swiss drugmaker said on Monday. (Source: Reuters: Health)

FDA grants priority review to Roche ’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)

MedWorm Message:

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus carboplatin and paclitaxel. (Source: Roche Media News)

Cipla ties up with Roche to sell 2 cancer drugs in India

The Economic Times Healthcare and Biotech News — Wed, 24 Apr 2024 11:51:33 +0100

The pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India. (Source: The Economic Times Healthcare and Biotech News)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema

Medscape Diabetes Headlines — Wed, 24 Apr 2024 11:51:33 +0100

In patients with diabetic macular edema (DME), aflibercept and ranibizumab are more effective than bevacizumab in preventing disease persistence, but each drug can lead to substantial gains in vision, according to a post hoc analysis of a randomized trial.Reuters Health Information (Source: Medscape Diabetes Headlines)

Two Anti-VEGF Agents Shine in DME Trial

MedPage Today Primary Care — Wed, 24 Apr 2024 11:51:33 +0100

(MedPage Today) -- Bevacizumab lags in three-way comparison (Source: MedPage Today Primary Care)

Combo Bests Targeted Agent in mRCC

MedPage Today Hematology/Oncology — Wed, 24 Apr 2024 11:51:33 +0100

(MedPage Today) -- Improved PFS with first-line atezolizumab and bevacizumab pairing (Source: MedPage Today Hematology/Oncology)

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)

Support for Upfront Immunotherapy in Advanced Renal Cell Cancer Support for Upfront Immunotherapy in Advanced Renal Cell Cancer

Medscape Medical News Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Atezolizumab plus bevacizumab improves progression-free survival with greater tolerability than standard sunitinib in advanced kidney cancer in a randomized controlled trial.Medscape Medical News (Source: Medscape Medical News Headlines)

IV Bevacizumab Effective for Severe HHT - Related Bleeding

The Doctors Lounge - Oncology — Wed, 24 Apr 2024 11:51:33 +0100

Drop in RBC transfusion requirements, epistaxis severity in hereditary hemorrhagic telangiectasia (Source: The Doctors Lounge - Oncology)

New and highly sensitive ELISA technique for bioanalysis of bevacizumab

EurekAlert! - Medicine and Health — Wed, 24 Apr 2024 11:51:33 +0100

(Bentham Science Publishers) Bevacizumab is an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, it is the antiangiogenic agent at the most advanced stage of development in the treatment of NSCLC.This drug was selected because of its inter individual differences in clinical response, its therapeutic importance in the treatment of non-small cell lung cancer (NSCLC). (Source: EurekAlert! - Medicine and Health)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Bevacizumab dramatically improves severe hereditary hemorrhagic telangiectasia (HHT) associated bleeding

EurekAlert! - Medicine and Health — Wed, 24 Apr 2024 11:51:33 +0100

(Elsevier) Patients with hereditary hemorrhagic telangiectasia (HHT) with severe bleeding, who were treated with intravenous bevacizumab, reported a marked reduction in nose bleeds and gastrointestinal bleeding and were able to stop or considerably reduce blood transfusions, resulting in significantly improved quality of life. A new study published in Mayo Clinic Proceedings provides good quality evidence for the excellent safety profile and efficacy of intravenous bevacizumab in the management of these patients. (Source: EurekAlert! - Medicine and Health)

No Survival Benefit with Bevacizumab Maintenance in CRC (CME/CE)

MedPage Today Gastroenterology — Wed, 24 Apr 2024 11:51:33 +0100

(MedPage Today) -- Monotherapy no better than observation after induction chemo (Source: MedPage Today Gastroenterology)

No Benefit With Bevacizumab Maintenance Therapy for Metastatic CRC During Chemo-Free Intervals

CancerNetwork — Wed, 24 Apr 2024 11:51:33 +0100

Adding bevacizumab maintenance therapy failed to improve outcomes compared with no treatment when administered during chemotherapy-free intervals to patients with metastatic colorectal cancer after induction chemotherapy. (Source: CancerNetwork)

European Commission Approves Amgen And Allergan's MVASI ® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

Amgen News Release — Wed, 24 Apr 2024 11:51:33 +0100

Marketing Authorization Based on Global Development Program Showing MVASI is Highly Similar to Avastin® (Bevacizumab) First Biosimilar Bevacizumab Approved in the European Union THOUSAND OAKS, Calif., Jan. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab). MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers, including in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma of the colon or rectum; in combination with paclitaxel for metastatic bre... (Source: Amgen News Release)

Tumor Microvessel Density as Marker for Bevacizumab Benefit Tumor Microvessel Density as Marker for Bevacizumab Benefit

Medscape Today Headlines — Wed, 24 Apr 2024 11:51:33 +0100

What are the potential predictive and prognostic effects of these five biomarkers in patients with ovarian cancer?Journal of the National Cancer Institute (Source: Medscape Today Headlines)

DelMar Pharma wins fast track status for glioblastoma drug

Mass Device — Wed, 24 Apr 2024 11:51:33 +0100

DelMar Pharmaceuticals (NSDQ:DMPI) said today that the FDA granted its lead product candidate, VAL-083, fast track status for approval as a therapy for recurrent glioblastoma. The designation applies to a Phase II trial with the University of Texas MD Anderson Cancer Center and a Phase III trial in patients whose disease has progressed after treatment with temozolomide and bevacizumab. Get the full story at our sister site, Drug Delivery Business News. The post DelMar Pharma wins fast track status for glioblastoma drug appeared first on MassDevice. (Source: Mass Device)

Phase III IMmotion151 Study Met Co-primary Goal In Kidney Cancer

Kidney Cancer Association — Wed, 24 Apr 2024 11:51:33 +0100

The study demonstrated that the combination of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death...12/12/2017 (Source: Kidney Cancer Association)

Roche: Tecentriq cocktail slows kidney cancer progression

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

ZURICH (Reuters) - Combining Roche's Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients, the Swiss drugmaker said on Monday (Source: Reuters: Health)

Phase III IMmotion151 study showed Roche ’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: Expression ≥1%) protein compared with sunitinib for the fir st-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced results from the positive, pivotal Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (carboplatin and paclitaxel) in people with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)

FDA grants Roche ’s Avastin full approval for most aggressive form of brain cancer

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Roche announced today that the U.S. Food and Drug Administration (FDA) has granted full approval for Avastin ® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). (Source: Roche Investor Update)

Poor regulation, dodgy pills spur plan for African drugs agency

Reuters: Health — Wed, 24 Apr 2024 11:51:33 +0100

LONDON (Reuters) - Last July, Ugandan officials seized fake versions of the cancer drug Avastin on sale in Kampala, revealing only the tip of an iceberg of bogus medicines found all too often in Africa. (Source: Reuters: Health)

MedWorm Message:

French Oncologists Upgrade Mesothelioma Standard of Care

Asbestos and Mesothelioma News — Wed, 24 Apr 2024 11:51:33 +0100

Oncologists throughout France have joined the U.S.-based National Comprehensive Cancer Network (NCCN) in upgrading their recommended standard-of-care treatment regimen for unresectable pleural mesothelioma. Both groups have added bevacizumab (Avastin) to the traditional cisplatin and pemetrexed chemotherapy combination, expecting to see longer patient survival. “This is a major advancement for the care of mesothelioma patients,” Dr. Gerard Zalcman, head of thoracic oncology at Bichat-Claude Bernard Hospital, told Asbestos.com. “Clearly, this drug can change the natural history of this tumor.” Bevacizumab is known as an angiogenesis drug. It works by inhibiting a specific protein that stimulates the formation of new blood vessels in tumors, effectively slowing the growth of cancer c...

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer

Roche Media News — Wed, 24 Apr 2024 11:51:33 +0100

Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advan ced non-squamous non-small cell lung cancer (NSCLC). Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These data are not fully mature and the next OS analysis is expected in the first half of 2018. Safety for the TECENTRIQ and Avastin plus chemotherapy combi nation appeared consistent...

EU Panel Likes Biosimilar Bevacizumab, Other Cancer Agents EU Panel Likes Biosimilar Bevacizumab, Other Cancer Agents

Medscape Medical News Headlines — Wed, 24 Apr 2024 11:51:33 +0100

The Committee for Medicinal Products for Human Use has issued a new list of recommendations and rejections for oncology products.International Approvals (Source: Medscape Medical News Headlines)

Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

HSMN NewsFeed — Wed, 24 Apr 2024 11:51:33 +0100

First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval THOUSAND OAKS, Calif., Nov. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the Commit... Biopharmaceuticals, Oncology, Regulatory Amgen, Allergan, biosimilar, Avastin, bevacizumab (Source: HSMN NewsFeed)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Review Shows Bevacizumab Has Gained Momentum for Mesothelioma...

PRWeb: Medical Pharmaceuticals — Wed, 24 Apr 2024 11:51:33 +0100

The VEGF inhibitor is now part of the standard treatment for pleural mesothelioma in France and a recognized first-line option for American clinicians.(PRWeb November 06, 2017)Read the full story at http://www.prweb.com/releases/2017/11/prweb14884392.htm (Source: PRWeb: Medical Pharmaceuticals)

Taxpayers pay twice for crucial drugs like Avastin | Letters

Guardian Unlimited Science — Wed, 24 Apr 2024 11:51:33 +0100

Big pharma companies are charging over the odds for medicines developed with public funding, writeHeidi Chow andTabitha HaIt is shocking, but not surprising, that big drugs companies are threatening to sue the NHS for using cheaper versions of drugs that could save people from going blind (Drug firms trying to stop cheap eye treatment on NHS, 1 November). Another part of this story is that the two medicines in question – Lucentis (known generically as ranibizumab) and Avastin (bevacizumab) are based on the groundbreaking discovery of monoclonal antibodies, whichwere developed with UK public funding.The NHS itself funded the trials to show that off-licence use of Avastin is as good as Lucentis, a finding that benefits patients not just in the UK but also globally. So the taxpayer is ...

Policy and regulation stand in the way of NHS use of unlicensed eye injection drug with potential to save millions of pounds

University of Bristol news — Wed, 24 Apr 2024 11:51:33 +0100

Eye injection drugs recommended by NICE cost the NHS up to £ 447 million annually, but could be replaced by an unlicensed drug, bevacizumab, costing as much as ten times less. Use of the two licensed drugs, ranibizumab and aflibercept, has increased three-fold over the last five years, with some parts of England treating five times as many patients as others. (Source: University of Bristol news)

MedWorm Message:

Health chiefs facing legal fight over cheaper eye drug

BBC News | Health | UK Edition — Wed, 24 Apr 2024 11:51:33 +0100

Prescribing Avastin will save the NHS "millions of pounds", health bosses say. (Source: BBC News | Health | UK Edition)

Doctors face legal action over use of unlicensed eye drug

OnMedica Latest News — Wed, 24 Apr 2024 11:51:33 +0100

They want to prescribe Avastin for wet AMD rather than costlier alternatives Related items fromOnMedica UK patients losing out in access to cancer drugs Drug and Therapeutics Update UK ‘inadequate’ at regulating off-label drugs GMC steps into eye drug row Novartis accused of attempt to derail eye drug trials (Source: OnMedica Latest News)

FDA accepts Roche ’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer

Roche Investor Update — Wed, 24 Apr 2024 11:51:33 +0100

Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of women with advanced ovarian cancer. (Source: Roche Investor Update)

Mvasi (Bevacizumab-awwb Solution for Intravenous Infusion) - new on RxList

RxList - New and Updated Drug Monographs — Wed, 24 Apr 2024 11:51:33 +0100

(Source: RxList - New and Updated Drug Monographs)

Laser May Be Safer Than Bevacizumab in Babies With Acute-phase ROP Laser May Be Safer Than Bevacizumab in Babies With Acute-phase ROP

Medscape Medical News Headlines — Wed, 24 Apr 2024 11:51:33 +0100

Babies with acute-phase retinopathy of prematurity (ROP) who are treated with bevacizumab have more long-term eye problems than babies treated with laser, according to a new randomized controlled trial done in Italy.Reuters Health Information (Source: Medscape Medical News Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. 100% free.

Amgen and Allergan ’s anti-cancer biosimilar Mvasi receives FDA approval

Pharmaceutical Technology — Wed, 24 Apr 2024 11:51:33 +0100

The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. (Source: Pharmaceutical Technology)

FDA has approved biosimilar of Roche's Avastin

Kidney Cancer Association — Wed, 24 Apr 2024 11:51:33 +0100

Amgen Inc. AMGN, -1.37% and Allergan AGN, -1.08% said Thursday that the Food and Drug Administration has approved their biosimilar version of Roche's Avastin for five types of cancer.09/15/2017 (Source: Kidney Cancer Association)

Mvasi Is First Biosimilar Drug Approved for Cancer

Cancercompass News: Other Cancer — Wed, 24 Apr 2024 11:51:33 +0100

Similar to Avastin (Source: Cancercompass News: Other Cancer)

FDA Approves First Biosimilar Drug for Cancer

The Doctors Lounge - Oncology — Wed, 24 Apr 2024 11:51:33 +0100

Mvasi (bevacizumab - awwb) is biosimilar to Avastin (Source: The Doctors Lounge - Oncology)

Mvasi Is First Biosimilar Drug Approved for Cancer

The Doctors Lounge - Oncology — Wed, 24 Apr 2024 11:51:33 +0100

Similar to Avastin (Source: The Doctors Lounge - Oncology)

MedWorm Message:

FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin

Drugs.com - New Drug Approvals — Wed, 24 Apr 2024 11:51:33 +0100

September 14, 2017 -- The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the... (Source: Drugs.com - New Drug Approvals)

FDA Approves Amgen And Allergan's MVASI ™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

Amgen News Release — Wed, 24 Apr 2024 11:51:33 +0100

Approval Based on Totality of Evidence From Global Development Program Showing MVASI™ is Highly Similar to Avastin® (bevacizumab) First Ever Biosimilar to Fight Cancer Approved by FDA THOUSAND OAKS, Calif., Sept. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin® (bevacizumab). MVASI is the first anti-cancer biosimilar, as well as the first bevacizumab biosimilar, approved by the FDA. MVASI is approved for the treatment of five types of cancer, including in combination with chemot... (Source: Amgen News Release)

First Oncology Biosimilar Approved in US: Bevacizumab First Oncology Biosimilar Approved in US: Bevacizumab

Medscape Medical News Headlines — Wed, 24 Apr 2024 11:51:33 +0100

The FDA has approved the first biosimilar for use in the treatment of cancer: Myasi, or bevacizumab-awwb (equivalent to Avastin).News Alerts (Source: Medscape Medical News Headlines)

Mvasi Is First Biosimilar Drug Approved for Cancer

Drugs.com - Daily MedNews — Wed, 24 Apr 2024 11:51:33 +0100

THURSDAY, Sept. 14, 2017 -- The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was found to be biosimilar to the anti-cancer drug Avastin, the FDA said Thursday in a news... (Source: Drugs.com - Daily MedNews)

ExcitingAds! Avastin

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

EMA Approves Ocular Formulation of Bevacizumab EMA Approves Ocular Formulation of Bevacizumab

Lonsurf/Bevacizumab for Advanced Metastatic Colorectal Cancer Lonsurf/Bevacizumab for Advanced Metastatic Colorectal Cancer

Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline

Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer

Atezolizumab Plus Standard Care Improves Survival in Advanced Cervical Cancer

FDA Approves Avzivi (bevacizumab-tnjn), a Biosimilar to Avastin

Adding Atezolizumab Improves Survival in Advanced Cervical Cancer

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, …

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products

No Benefit to Extending Bevacizumab in Ovarian Cancer No Benefit to Extending Bevacizumab in Ovarian Cancer

FDA Approves Lonsurf (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC)

FDA OKs Trifluridine/Tipiracil Plus Bevacizumab for mCRC FDA OKs Trifluridine/Tipiracil Plus Bevacizumab for mCRC

FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer

Sticker Shock: Ophthalmic Bevacizumab Biosimilar Could Drive Up Costs

What Are Treatments for Recurrent Respiratory Papillomatosis?

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products

Can AI Help Determine If Liver Cancer Will Respond to Standard Treatment?

Trial Suggests Optimal Approach to Unresectable CRC Liver Mets

ASCO: Adding Pembrolizumab to Chemo Improves Survival in Cervical Cancer

Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023

FTD-TPI Plus Bevacizumab Increases Survival in Refractory Advanced CRC

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests

Combo Therapy May Prevent Cancer's Return After Liver Surgery

Health Highlights: April 24, 2023 ​

AACR: Adjuvant Atezolizumab + Bevacizumab Beneficial in Liver Cancer

Drug Combo Improves Recurrence-Free Survival After HCC Resection Drug Combo Improves Recurrence-Free Survival After HCC Resection

Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study

Genentech ending commercial manufacturing, 265 jobs at 40-year-old South S.F. facility

USFDA issues CRL for Bevacizumab license application moved by Viatris: Biocon

No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products

New Standard of Care for Refractory Metastatic Colorectal Cancer

SUNLIGHT: New Standard of Care in Refractory Metastatic CRC SUNLIGHT: New Standard of Care in Refractory Metastatic CRC

[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial

Atezolizumab Plus Bevacizumab: A New Standard for Some NSCLC? Atezolizumab Plus Bevacizumab: A New Standard for Some NSCLC?

Shaken baby syndrome in an infant treated for retinopathy of prematurity with anti-VEGF injection - Devebacak A, Bekmez S, Eris E, Mayali H, Yurtseven I, Celik Y, Ba ğ Ö.

Bevacizumab, Aflibercept Compared for Neovascular AMD

FDA Approves Elahere (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer

[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022

FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin

[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022

Diabetic Macular Edema Outcomes Compared for Aflibercept, Bevacizumab

Bevacizumab First Matches Aflibercept for Diabetic Macular Edema Bevacizumab First Matches Aflibercept for Diabetic Macular Edema

Panitumumab Beats Bevacizumab in Left-Sided mCRC Panitumumab Beats Bevacizumab in Left-Sided mCRC

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare

Which CRC Regimens Are More Likely to Harm Kidneys? Which CRC Regimens Are More Likely to Harm Kidneys?

Alymsys (Bevacizumab-maly Injection) - updated on RxList

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022

Alymsys (Bevacizumab-maly Injection) - new on RxList

FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin

Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021

Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy

Bevacizumab and Gastrointestinal Perforations Bevacizumab and Gastrointestinal Perforations

Bevacizumab-vikg Wet AMD Trial Raises Eyebrows Bevacizumab-vikg Wet AMD Trial Raises Eyebrows

New Standard of Care in Cervical Cancer New Standard of Care in Cervical Cancer

Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine

Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease

New Drug Combination Shows Promise for Peritoneal Mesothelioma

Oncotarget: RAS reversion in colorectal cancer patients treated with bevacizumab

Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient

Edge Pharma Announces New Agreement with Cardinal Health ’s Acuity™ GPO

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

Drug Combination Disappoints in Advanced NSCLC Drug Combination Disappoints in Advanced NSCLC

Intravitreal bevacizumab cost saving for macular oedema in the UK

Genentech defends breast cancer drug a decade after Avastin drama

New Combo Shows Benefit Even in Patients With High-Risk HCC New Combo Shows Benefit Even in Patients With High-Risk HCC

Biocon Biologics, Viatris Inc. get CHMP nod for Abevmy, a biosimilar to Avastin

Atezolizumab + bevacizumab unlikely cost-effective first-line option in HCC

Anticancer drug may improve outcome for severe COVID-19 patients

Drug 'breakthrough' gives longest-ever survival in nonresectable liver cancer patients

Researchers: Mesothelioma Trials Need More Inclusive Criteria

Jury's Still Out on Trifluridine/Tipiracil Plus Bev in mCRC Jury's Still Out on Trifluridine/Tipiracil Plus Bev in mCRC

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer

USFDA informs Biocon Biologics, Mylan of deferred action on Avastin biosimilar license application

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Biomarker Predicts Severe Hypertension With Bevacizumab Biomarker Predicts Severe Hypertension With Bevacizumab

Health Highlights: April 24, 2023